Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Lotiglipron

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

Pfizer · Phase 2 · Terminated · Enrollment 902

NCT05579977

EudraCT 2022-002834-15

ArmPopulationDoseWeeksEstimandWeight change
PF-07081532 20 mg T2DMObesity + T2D20 mg36n/rn/r
PF-07081532 40 mg T2DMObesity + T2D40 mg36n/rn/r
PF-07081532 80 mg T2DMObesity + T2D80 mg36n/rn/r
PF-07081532 160 mg T2DMObesity + T2D160 mg36n/rn/r
PF-07081532 260 mg T2DMObesity + T2D260 mg36n/rn/r
Placebo T2DMObesity + T2Dn/r36n/rn/r
PF-07081532 80 mg ObesityObesity + T2D80 mg36n/rn/r
PF-07081532 140 mg ObesityObesity + T2D140 mg36n/rn/r
PF-07081532 200 mg Obesity (Option 1)Obesity + T2D200 mg36n/rn/r
PF-07081532 200 mg Obesity (Option 2)Obesity + T2D200 mg36n/rn/r
PF-07081532 260 mg ObesityObesity + T2D260 mg36n/rn/r
Rybelsus 14 mg T2DMObesity + T2D14 mg36n/rn/r
Placebo ObesityObesity + T2Dn/r36n/rn/r